The paper, which summarises the results of studies led by Associate Professor James Chong (Westmead Institute for Medical Research, Sydney), validates the importance of Cymerus MSCs in treating serious and debilitating diseases and provides further recognition of Cynata’s advanced technology.
Cynata has signed a worldwide licence agreement with TekCyte Pty Ltd for TekCyte’s novel wound dressing technology for use in Cynata’s upcoming diabetic foot ulcer trial (short scroll down)
Cynata CEO Dr Ross Macdonald appears on Kalkine TV’s “Expert Corner” to discuss the Company’s quarterly results and provides an update on its MEND trial and worldwide exclusive licence agreement with TekCyte Pty Ltd.
Channel 9 Health Reporter Gabriella Rogers explores the potential therapeutic benefits of Cynata’s MSC product in this serious disease and reviews the SCULpTOR trial with Professor David Hunter
Addressing The Challenges Of MSCs Will Reveal A Bright Future For This Regenerative Medicine Modality.